

# Suzie Lavoie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1615554/publications.pdf>

Version: 2024-02-01

34  
papers

1,557  
citations

394421

19  
h-index

414414

32  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2678  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2008, 33, 2187-2199.	5.4	321
2	Biomarkers and clinical staging in psychiatry. <i>World Psychiatry</i> , 2014, 13, 211-223.	10.4	243
3	Phase Relationships between Sleep-Wake Cycle and Underlying Circadian Rhythms in Morningness-Eveningness. <i>Journal of Biological Rhythms</i> , 2004, 19, 248-257.	2.6	210
4	Curcumin, quercetin, and tBHQ modulate glutathione levels in astrocytes and neurons: importance of the glutamate cysteine ligase modifier subunit. <i>Journal of Neurochemistry</i> , 2009, 108, 1410-1422.	3.9	95
5	Declining transition rates to psychotic disorder in "ultra-high risk" clients: Investigation of a dilution effect. <i>Schizophrenia Research</i> , 2016, 170, 130-136.	2.0	87
6	Dysconnection Topography in Schizophrenia Revealed with State-Space Analysis of EEG. <i>PLoS ONE</i> , 2007, 2, e1059.	2.5	58
7	Clinical trajectories in the ultra-high risk for psychosis population. <i>Schizophrenia Research</i> , 2018, 197, 550-556.	2.0	54
8	Vigilance Levels During and After Bright Light Exposure in the First Half of the Night. <i>Chronobiology International</i> , 2003, 20, 1019-1038.	2.0	46
9	Sulcogyral pattern and sulcal count of the orbitofrontal cortex in individuals at ultra high risk for psychosis. <i>Schizophrenia Research</i> , 2014, 154, 93-99.	2.0	40
10	Influence of sleep stage and wakefulness on spectral EEG activity and heart rate variations around periodic leg movements. <i>Clinical Neurophysiology</i> , 2004, 115, 2236-2246.	1.5	37
11	Heart rate activation during spontaneous arousals from sleep: effect of sleep deprivation. <i>Clinical Neurophysiology</i> , 2004, 115, 2442-2451.	1.5	35
12	Duration of untreated psychosis: a proposition regarding treatment definition. <i>Microbial Biotechnology</i> , 2011, 5, 301-308.	1.7	33
13	Impaired mismatch negativity to frequency deviants in individuals at ultra-high risk for psychosis, and preliminary evidence for further impairment with transition to psychosis. <i>Schizophrenia Research</i> , 2018, 191, 95-100.	2.0	31
14	A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons. <i>Free Radical Biology and Medicine</i> , 2008, 44, 1042-1054.	2.9	26
15	Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis. <i>Schizophrenia Research</i> , 2012, 138, 206-211.	2.0	26
16	The construct validity of the Inventory of Psychotic-Like Anomalous Self-Experiences (IPASE) as a measure of minimal self-disturbance: Preliminary data. <i>Microbial Biotechnology</i> , 2019, 13, 686-691.	1.7	24
17	Testing a neurophenomenological model of basic self disturbance in early psychosis. <i>World Psychiatry</i> , 2019, 18, 104-105.	10.4	23
18	Altered Glycogen Metabolism in Cultured Astrocytes from Mice with Chronic Glutathione Deficit; Relevance for Neuroenergetics in Schizophrenia. <i>PLoS ONE</i> , 2011, 6, e22875.	2.5	22

#	ARTICLE	IF	CITATIONS
19	Staging model in psychiatry: Review of the evolution of electroencephalography abnormalities in major psychiatric disorders. <i>Microbial Biotechnology</i> , 2019, 13, 1319-1328.	1.7	22
20	Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 292-299.	8.8	20
21	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. <i>Behaviour Research and Therapy</i> , 2020, 124, 103527.	3.1	16
22	Relationship between allostatic load and clinical outcomes in youth at ultra-high risk for psychosis in the NEURAPRO study. <i>Schizophrenia Research</i> , 2020, 226, 38-43.	2.0	13
23	The relation of basic self-disturbance to self-harm, eating disorder symptomatology and other clinical features: Exploration in an early psychosis sample. <i>Microbial Biotechnology</i> , 2020, 14, 275-282.	1.7	12
24	Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population. <i>Microbial Biotechnology</i> , 2021, 15, 642-651.	1.7	11
25	Distinguishing schizophrenia spectrum from non-spectrum disorders among young patients with first episode psychosis and at high clinical risk: The role of basic self-disturbance and neurocognition. <i>Schizophrenia Research</i> , 2021, 228, 19-28.	2.0	11
26	Harmonised collection of data in youth mental health: Towards large datasets. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 46-56.	2.3	8
27	The relationship between childhood trauma and clinical characteristics in ultra-high risk for psychosis youth. <i>Psychosis</i> , 2019, 11, 28-41.	0.8	6
28	Frontal slow wave resting EEG power is higher in individuals at Ultra High Risk for psychosis than in healthy controls but is not associated with negative symptoms or functioning. <i>Schizophrenia Research</i> , 2019, 208, 293-299.	2.0	6
29	Glutamate Cysteine Ligase $\alpha$ Modulatory Subunit Knockout Mouse Shows Normal Insulin Sensitivity but Reduced Liver Glycogen Storage. <i>Frontiers in Physiology</i> , 2016, 7, 142.	2.8	5
30	Correlates of electroencephalographic resting states and erythrocyte membrane docosahexaenoic and eicosapentaenoic acid levels in individuals at ultra-high risk of psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 56-63.	2.3	5
31	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	3.1	5
32	Greater preference for eveningness is associated with negative symptoms in an ultra-high risk for psychosis sample. <i>Microbial Biotechnology</i> , 2021, 15, 1793-1798.	1.7	4
33	Patients <sup>TM</sup> , carers <sup>TM</sup> and clinicians <sup>TM</sup> attitudes towards alternative terms to describe the at-risk for psychosis state. <i>Schizophrenia Research</i> , 2021, 237, 69-75.	2.0	1
34	Electroencephalography and Staging. , 2019, , 204-220.		0